EQL Pharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 3/6
EQL Pharma heeft een totaal eigen vermogen van SEK197.9M en een totale schuld van SEK148.2M, wat de schuld-eigenvermogensverhouding op 74.9% brengt. De totale activa en totale passiva bedragen respectievelijk SEK423.3M en SEK225.4M. De EBIT EQL Pharma is SEK47.7M waardoor de rentedekking 5.9 is. Het heeft contanten en kortetermijnbeleggingen van SEK11.8M.
Belangrijke informatie
74.9%
Verhouding schuld/eigen vermogen
SEK 148.22m
Schuld
| Rente dekkingsratio | 5.9x |
| Contant | SEK 11.83m |
| Aandelen | SEK 197.89m |
| Totaal verplichtingen | SEK 225.41m |
| Totaal activa | SEK 423.30m |
Recente financiële gezondheidsupdates
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
Aug 12
Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29Recent updates
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
Oct 29EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 22Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
Aug 12EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
Jun 13EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
May 14EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?
Dec 28What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?
Dec 11EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment
Nov 22Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( SEK232.7M ) EQL } overtreffen de korte termijn passiva ( SEK186.9M ).
Langlopende schulden: De kortetermijnactiva EQL ( SEK232.7M ) overtreffen de langetermijnschulden ( SEK38.5M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 68.9% ) EQL wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van EQL is de afgelopen 5 jaar gestegen van 0% naar 74.9%.
Schuldendekking: De operationele kasstroom van EQL is negatief, waardoor de schuld niet goed gedekt is.
Rentedekking: De rentebetalingen op de schuld van EQL worden goed gedekt door EBIT ( 5.9 x dekking).